Neuropace revenue was $71.82M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2024) ending on Jun 30, 2024 was $19.3M, up 6.2% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, NPCE annual revenue was $65.4M, with 43.7% growth year-over-year.
NPCE past revenue growth
How has NPCE's revenue growth performed historically?
On Invalid Date, Neuropace (NASDAQ: NPCE) reported Q2 2024 revenue of $19.26 million up 16.63% year over year. In the same quarter last year, Neuropace's revenue was $16.51 million.
What was Neuropace's revenue in 2023?
Neuropace's annual revenue for the twelve months ending Dec 31, 2023 was $65.42 million, a 43.72% increase year over year.
How much does Neuropace make in a day?
Based on Neuropace annual revenue for the past four years, NPCE makes an average of $135,110.96 per day.
What was Neuropace's annual revenue growth in the past year?
As of Q4 2024, Neuropace's revenue has grown 30.75% year over year. This is 19.78 percentage points higher than the US Medical Devices industry revenue growth rate of 10.98%. Neuropace's revenue in the past year totaled $71.82 million.
How much does Neuropace make in a year?
Neuropace's revenue by year for the past four years is:
Neuropace's revenue for the twelve months ending Dec 31, 2023 was $65.42 million, a 43.72% increase year over year.
Neuropace's annual revenue for Dec 31, 2022 was $45.52 million, a 0.75% increase from 2021.
Neuropace's annual revenue for 2021 was $45.18 million, a 9.83% increase from 2020.
Neuropace's annual revenue for 2020 was $41.14 million, a 11.27% increase from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.